Influx Healthtech reports FY26 revenue of INR146 crores

Influx Healthtech Limited reported a financial performance for FY26 with revenue from operations reaching INR146 crores, a 41% year-on-year growth in H2 FY26. The company’s Profit After Tax (PAT) for the full year stood at INR20.5 crores, with a PAT margin of 14%. EBITDA for the year was INR29.9 crores, reflecting a margin of 20.3%.

Financial Highlights

The company’s operational efficiency improved as the cash conversion cycle reduced to 64 days in FY26 from the previous year. Inventory days decreased to 99 days from 112 days in FY25, while debtor days improved to 84 days from 113 days.

Metric	FY26 Value
Revenue from Operations	INR146 crores
PAT	INR20.5 crores
EBITDA	INR29.9 crores
Cash Surplus	INR25.2 crores
Return on Equity	30%

Operational Updates

Influx Healthtech commissioned a new granulation line for tablet manufacturing with a capacity of 480 kg per day. The company is developing a new facility of approximately 75,000 square feet, expected to be operational by July or August 2026. This expansion is anticipated to increase overall installed capacity by 2.5 times. Additionally, the company incorporated a wholly owned subsidiary, Olahey Wellness Private Limited, to manufacture ready-to-drink wellness beverages.

Future Guidance

The management stated that the company aims to grow by 25% to 30% in FY27 with similar margins. The Board has approved the reallocation of INR10 crores from IPO proceeds, primarily from surplus amounts, towards the enhanced construction cost for the nutraceutical CDMO facility.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+7.61%	-10.47%	-0.46%	+9.84%	+98.22%	+98.22%

Influx Healthtech Limited has reported its audited financial results for the fiscal year ended March 31, 2026. The company recorded a 54.3% year-on-year increase in net profit to Rs 2,054.13 lakh, up from Rs 1,331.40 lakh in the previous year. Revenue from operations for FY26 stood at Rs 14,683.36 lakh, marking a 40% growth compared to Rs 10,485.36 lakh in FY25.

Financial Performance Overview

The company’s earnings per share (EPS) improved to Rs 9.35 for FY26 from Rs 7.31 in the previous year. EBITDA for the full year reached Rs 2,986.13 lakh, a 45.2% increase, with an EBITDA margin of 20.3%. For the half-year ended March 31, 2026 (H2 FY26), revenue stood at Rs 8,006.90 lakh, while net profit was Rs 1,054.59 lakh.

Metric	FY26 (Rs. in Lakhs)	FY25 (Rs. in Lakhs)	YoY Change
Revenue from Operations	14,683.36	10,485.36	+40%
EBITDA	2,986.13	2,057.10	+45.2%
Net Profit	2,054.13	1,331.40	+54.3%
Basic EPS (Rs.)	9.35	7.31	+27.9%

Segment and Operational Highlights

The Nutraceuticals segment remained the dominant revenue contributor, accounting for approximately 90% of FY26 revenue with a 40.3% YoY growth to Rs 13,190.58 lakh. The Ayurvedic segment grew 88.9% to Rs 611.77 lakh, while the Cosmetics segment increased 15.8% to Rs 742.42 lakh.

Operationally, the company invested Rs 60 lakhs to boost tablet capacity and secured a 5-year FSSAI license for a new facility. It received compliance approval with Good Manufacturing Practices (GMP) to expand into the Tanzania market and incorporated Olahey Wellness Private Limited to manufacture Ready-to-Drink beverages.

Corporate Governance

The Board appointed M/s. Phirodia bafna & Associates as Internal Auditors for FY27. The statutory auditors, M/s V. B. Goel & Co., issued an unmodified opinion on the financial results. The company successfully listed on the NSE Emerge platform in June 2025, raising net proceeds of Rs 4,474.75 lakh.